

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3944579

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	S*BIO PTE LTD.	08/22/2012
RECEIVING PARTY DATA		
Name:	MEI PHARMA, INC.	
Street Address:	11975 EL CAMINO REAL, SUITE 101	
City:	SAN DIEGO	
State/Country:	CALIFORNIA	
Postal Code:	92130	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	15178742
CORRESPONDENCE DATA		
Fax Number:	(650)493-6811	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	650-493-9300	
Email:	uspatentdocket@wsgr.com	
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI	
Address Line 1:	650 PAGE MILL ROAD	
Address Line 4:	PALO ALTO, CALIFORNIA 94304	
ATTORNEY DOCKET NUMBER:	40082-734.303	
NAME OF SUBMITTER:	LINDA ANDERS	
SIGNATURE:	/Linda Anders/	
DATE SIGNED:	06/30/2016	
Total Attachments: 12		
source=40082-734-303-assignmentSBIOtoMEI#page1.tif		
source=40082-734-303-assignmentSBIOtoMEI#page2.tif		
source=40082-734-303-assignmentSBIOtoMEI#page3.tif		
source=40082-734-303-assignmentSBIOtoMEI#page4.tif		
source=40082-734-303-assignmentSBIOtoMEI#page5.tif		
source=40082-734-303-assignmentSBIOtoMEI#page6.tif		

source=40082-734-303-assignmentSBItoMEI#page7.tif
source=40082-734-303-assignmentSBItoMEI#page8.tif
source=40082-734-303-assignmentSBItoMEI#page9.tif
source=40082-734-303-assignmentSBItoMEI#page10.tif
source=40082-734-303-assignmentSBItoMEI#page11.tif
source=40082-734-303-assignmentSBItoMEI#page12.tif

ASSIGNMENT

August 22, 2012

WHEREAS, **S**BIO Pte Ltd.*** “Assignor”, a private limited company duly organized under and pursuant to the laws of Singapore, and having its principal place of business at 250 North Bridge Rd #28-00 Raffles City Tower, Singapore 179101 (herein referred to as “Assignor”) owns the entire right, title and interest in any Letters Patent(s) (“said patent(s)”) and any Patent application(s) (“said application(s)”) set forth in attached Exhibit D, as well as any invention(s) (“said invention(s)”) disclosed in said application(s) and said patent(s);

WHEREAS, **MEI PHARMA, INC.**, “Assignee” a corporation of the State of Delaware, and having its principal place of business at 11975 El Camino Real, Suite 101, San Diego, CA 92130, is desirous of acquiring the entire right, title and interest in and to said invention(s), said application(s), and said patent(s), the right to file applications on said invention(s), the entire right, title and interest in and to any applications for Letters Patent of the United States or other countries claiming priority to said application(s), the right to recover damages, including provisional or other royalties, for prior infringements of said application(s) and said patent(s), and the entire right, title, and interest in and to any Letters Patent or Patents, United States or foreign, to be obtained for said invention(s) and said application(s);

NOW, THEREFORE, FOR GOOD AND VALUABLE CONSIDERATION, the receipt of which is hereby acknowledged, Assignor does hereby sell, assign and transfer to **MEI PHARMA, INC.**, its successors and assigns, the entire right, title and interest in and to: said invention(s), said application(s), and said patent(s), the right to file applications on said invention(s); any and all applications filed in any country based thereon, including the right to file applications in countries other than the country of priority filing under the provisions of any international convention; any and all patents, including reissues and extensions thereof, obtained in any country upon said inventions; any and all continuing applications, including divisional, continuation and continuation-in-part applications; any substitute applications; all prior applications disclosing said inventions to which the present application claims priority; and to any other applications claiming the benefit of said prior applications.

Assignors hereby authorize and request the issuing authority to issue any and all patents on said application or applications to **MEI PHARMA, INC.**, as assignee of the entire interest.

This Assignment may be executed in any number of counterparts; and each such counterpart hereof shall be deemed to be an original instrument; but all such counterparts together shall constitute but one agreement. Delivery of an executed counterpart of a signature page of this Assignment by facsimile or other electronic transmission shall be effective as delivery of a manually executed original counterpart of this Assignment.


[remainder of page intentionally left blank.]

IN WITNESS WHEREOF, the undersigned have caused this Assignment to be duly executed and delivered as of the date first written above.

S*~~B~~IO Pte Ltd.

By:

Name/Title:



Choo HENG TONG

/ CHAIRMAN

MEI Pharma, Inc.

By:

Name/Title:

IN WITNESS WHEREOF, the undersigned have caused this Assignment to be duly executed and delivered as of the date first written above.

S*BIO Pte Ltd.

By: _____

Name/Title: _____

MEI Pharma, Inc.

By:  _____

Name/Title: Daniel P. Gold, President & Chief Executive Officer

Exhibit D

ASSIGNMENT OF PATENTS AND PATENT APPLICATIONS

1. Patents and patent applications titled: "BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS":

Owner	S*BIO Pte Ltd.
Priority Information	US 60/530,890 - 22 December 2003 US 60/504,214 - 22 September 2003
PCT Application Number	PCT/SG2004/000307
PCT Filing Date	21 September 2004

Jurisdiction	Application No. (Granted No.)	Filing Date or National phase entry date (dd/mm/yyyy)	Grant date (if applicable) (dd/mm/yyyy)
Argentina	P04 01 03390	21/09/2004	
Australia	2004274382 (2004274382)	21/09/2004	23/05/2011
Brazil	P10414581-0	21/09/2004	
Canada	2539766	21/09/2004	
China	200480027330.4 (ZL 200480027330.4)	21/09/2004	07/10/2009
Europe (see countries below)	04775628.3 (1673349)	21/09/2004	30/06/2010
• Austria	1673349		
• Belgium	1673349		
• Bulgaria	1673349		
• Cyprus	1673349		
• Czech Republic	1673349		
• Denmark	1673349		
• Estonia	1673349		
• Finland	1673349		
• France	1673349		

*List of Patents - Patent Assignment - S*Bio to MEI Pharma*

Jurisdiction	Application No. (Granted No.)	Filing Date or National phase entry date (dd/mm/yyyy)	Grant date (if applicable) (dd/mm/yyyy)
• Germany	1673349		
• Greece	1673349		
• Hungary	1673349		
• Ireland	1673349		
• Italy	1673349		
• Luxembourg	1673349		
• Monaco	1673349		
• Netherlands	1673349		
• Poland	1673349		
• Portugal	1673349		
• Romania	1673349		
• Slovak Republic	1673349		
• Slovenia	1673349		
• Spain	1673349		
• Sweden	1673349		
• Switzerland	1673349		
• Turkey	1673349		
United Kingdom	1673349		
India	1034/KOLNP/2006 (246789)	21/09/2004	16/03/2011
Indonesia	W00200601031 (P0027283)	21/09/2004	17/12/2010
Japan	2006-527948	21/09/2004	
Korea	10-2006-7005698 (10-1127201)	21/09/2004	08/03/2012

List of Patents – Patent Assignment – S*Bio to MEI Pharma

Jurisdiction	Application No. (Granted No.)	Filing Date or National phase entry date (dd/mm/yyyy)	Grant date (if applicable) (dd/mm/yyyy)
Malaysia	PI20043871 (MY-142589-A)	21/09/2004	15/12/2010
Mexico	PA/A/2006/003190 (267171)	21/09/2004	03/06/2009
New Zealand	545864 (545864)	21/09/2004	08/04/2010
Philippines	1-2006-500519 (1-2006-500519)	21/09/2004	20/09/2010
Singapore	200601733-9 (120558)	21/09/2004	31/10/2007
South Africa	2006/02181 (2006/02181)	21/09/2004	27/06/2007
Taiwan	093128611 (1349664)	21/09/2004	01/10/2011
Thailand	093851	21/09/2004	
USA	10/572,958 (7,781,595)	21/09/2004	24/08/2010
USA	12/814,964	21/09/2004	
Vietnam	1-2006-00637 (9158)	21/09/2004	15/03/2011

List of Patents – Patent Assignment – S*Bio to MEI Pharma

2. Patents and patent applications titled: "HETEROCYCLIC COMPOUNDS"

Owner	S*Bio Pte Ltd.
Priority Information	US 60/714,827 - 8 September 2005 US 60/783,819 - 21 March 2006
PCT Application Number	PCT/SG2006/000217
PCT Filing Date	1 August 2006

Jurisdiction	Application No. (Granted No.)	Filing Date or National phase entry date (dd/mm/yyyy)	Grant date (if applicable) (dd/mm/yyyy)
Argentina	P060103353	01/08/2006	
Australia	2006201177	21/03/2006	
Brazil	P10615690-8	01/08/2006	
Canada	2540459	21/03/2006	
China	200680038327.1	01/08/2006	
Europe (see countries below)	06769700.3 (1937650)	01/08/2006	15/06/2011
• Austria	1937650		
• Belgium	1937650		
• Bulgaria	1937650		
• Cyprus	1937650		
• Czech Republic	1937650		
• Denmark	1937650		
• Estonia	1937650		
• Finland	1937650		
• France	1937650		
• Germany	1937650		
• Greece	1937650		
• Hungary	1937650		

List of Patents - Patent Assignment - S*Bio to MEI Pharma

Jurisdiction	Application No. (Granted No.)	Filing Date or National phase entry date (dd/mm/yyyy)	Grant date (if applicable) (dd/mm/yyyy)
• Iceland	1937650		
• Ireland	1937650		
• Italy	1937650		
• Latvia	1937650		
• Lithuania	1937650		
• Luxembourg	1937650		
• Monaco	1937650		
• Netherlands	1937650		
• Poland	1937650		
• Portugal	1937650		
• Romania	1937650		
• Slovak Republic	1937650		
• Slovenia	1937650		
• Spain	1937650		
• Sweden	1937650		
• Switzerland	1937650		
• Turkey	1937650		
• United Kingdom	1937650		
India	997/KOLNP/2008	01/08/2006	
Indonesia	W00200800763	01/08/2006	
Hong Kong	08114137.7 (HK1123038)	01/06/2006	15/06/2011

List of Patents – Patent Assignment – S*Bio to MEI Pharma

Jurisdiction	Application No. (Granted No.)	Filing Date or National phase entry date (dd/mm/yyyy)	Grant date (if applicable) (dd/mm/yyyy)
Japan	2008-529964	01/08/2006	
Malaysia	PI20063724	01/08/2006	
Mexico	MX/A/2008/003282 (290912)	01/08/2006	10/10/2011
New Zealand	594108	15/07/2011	
Philippines	1-2008-500585	01/08/2006	
Singapore	200802688-2 (141679)	01/08/2006	30/04/2009
South Africa	2008/03017 (2008/03017)	01/08/2006	28/10/2009
South Korea	10-2008-7007856	01/08/2006	
Taiwan	095128137	01/08/2006	
Thailand	0601003841	01/08/2006	
USA	12/065,989 (8,143,282)	01/08/2006	27/03/2012
Vietnam	1-2008-00852	01/08/2006	

List of Patents – Patent Assignment – S*Bio to MEI Pharma

3. Patents and patent applications titled: "COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT"

Owner	S*Bio Pte Ltd.
Priority Information	US 60/905,293 – 7 March 2007 US 60/905,299 – 7 March 2007
PCT Application Number	PCT/SG2008/000074
PCT Filing Date	7 March 2008

Jurisdiction	Application No.	Filing Date or National phase entry date (dd/mm/yyyy)	Grant date (if applicable) (dd/mm/yyyy)
Europe	08724338.2	07/03/2008	

List of Patents – Patent Assignment – S*Bio to MEI Pharma

4. Patents and patent applications titled: "IMIDAZO[1,2-A]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS"

Owner	S*Bio Pte Ltd
Priority Information	1. US 60/663,265 - 21 March 2005 2. US 60/759,544 - 18 January 2006
PCT Application Number	PCT/SG2006/000064
PCT Filing Date	20 March 2006

Jurisdiction	Application No. (Granted No.)	Filing Date or National phase entry date (dd/mm/yyyy)	Grant date (if applicable) (dd/mm/yyyy)
Australia	2006225355 (2006225355)	20/03/2006	24/03/2011
Canada	2602328	20/03/2006	
P.R. China	200680009253.9 (ZL 200680009253.9)	20/03/2006	26/10/2011
Europe	06717188.4	20/03/2006	
Japan	2008-502953	20/03/2006	
Republic of Korea	10-2007-7023609	20/03/2006	
Malaysia	PI 20061225	20/03/2006	11/01/2011
Mexico	MX/A/2007/011710 (282750)	20/03/2006	
Singapore	200716831-3 (137007)	20/03/2006	30/01/2009
Thailand	0601001258	20/03/2006	
U.S.A	11/857,807 (7,666,880)	20/03/2006	23/02/2010
U.S.A	12/651,052	20/03/2006	

List of Patents – Patent Assignment – S*Bio to MEI Pharma

5. Patents and patent applications titled: "IMIDAZO[1,2-A]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS"

Owner	S*BIO Pte Ltd
Priority Information	Direct PCT Filing
PCT Application Number	PCT/SG2006/000277
PCT Filing Date	20 September 2006

Jurisdiction	Application No. (Granted No.)	Filing Date or National phase entry date (dd/mm/yyyy)	Grant date (if applicable) (dd/mm/yyyy)
Europe	06784289.8	20/09/2006	

List of Patents – Patent Assignment – S*Bio to MEI Pharma